AMES, Iowa, April 1 /PRNewswire/ -- NewLink Genetics Corporation announced that it has taken occupancy of its new administrative and manufacturing facility. The building includes both a cGMP manufacturing suite as well as administrative and executive offices. It is located on the campus of the Iowa State University Research Park in Ames, Iowa.
"NewLink should be able to supply all of its clinical drug supply and initial commercial supply requirements for its lead pancreatic cancer therapy from this facility," said Dr. Charles Link, Chairman and Chief Executive Officer of NewLink Genetics Corporation. "In addition, we plan to eventually move all of our pilot manufacturing for a new series of HyperAcute cancer immunotherapies to this facility as well."
About the facility
This 23,000 square foot facility was built to NewLink's specifications and will eventually house all of its current administrative and manufacturing needs. More than 60% of the space is dedicated to cGMP manufacturing.
About NewLink Genetics Corporation
NewLink Genetics Corporation is a biopharmaceutical company applying innovative technologies to create new therapeutic agents for patients with cancer and infectious diseases. Its products are designed to enhance the patient's immune system, enabling the body's immune cells to target diseased tissues.
NewLink Genetics Corporation
Gordon Link, CFO, 515-598-2925
SOURCE NewLink Genetics Corporation